Neuropharmacology and analgesiaEffects of 5-HT1A receptor antagonists on hippocampal 5-hydroxytryptamine levels: (S)-WAY100135, but not WAY100635, has partial agonist properties
References (30)
- et al.
(−)-Pindolol and (±)-tertalolol affect rat hippocampal 5-HT levels through mechanisms involving not only 5-HT1A but also 5-HT1B
Neuropharmacology
(1996) - et al.
Suppression of firing activity of 5-HT neurons in the dorsal raphe by alpha-adrenoceptor antagonists
Neuropharmacology
(1980) - et al.
WAY100135: A novel, selective antagonist at presynaptic and post-synaptic 5-HT1A receptors
Eur. J. Pharmacol.
(1993) - et al.
A pharmacological profile of the selective silent 5-HT1A receptor antagonist, WAY100635
Eur. J. Pharmacol.
(1995) - et al.
Mixed agonist/antagonist properties of NAN-190 at 5-HT1A receptors: behavioural and in vivo brain microdialysis studies
Life Sci.
(1990) - et al.
Studies on the role of 5-HT1A autoreceptors and α1-adrenoceptors in the inhibition of 5-HT release. I. BMY7378 and prazosin
Neuropharmacology
(1995) - et al.
The presence of a serotonin uptake inhibitor alters pharmacological manipulations of serotonin release
Neuroscience
(1993) - et al.
Further assessment of the antagonist properties of the novel and selective 5-HT1A receptor ligands (+)-WAY100135 and SDZ 216–525
Eur. J. Pharmacol.
(1993) - et al.
Electrophysiological evidence that spiperone is an antagonist of 5- HT1A receptors in the dorsal raphe nucleus
Eur. J. Pharmacol.
(1988) - et al.
Effect of the putative 5-HT1A antagonists WAY100135 and SDZ 216–525 on 5-HT neuronal firing in the guinea-pig dorsal raphe nucleus
Neuropharmacology
(1994)
α1-Adrenoceptor antagonists differentially control serotonin release in the hippocampus and striatum: A microdialysis study
Eur. J. Pharmacol.
Neurochemical profile of the selective and silent 5-HT1A receptor antagonist WAY100135: An in vivo microdialysis study
Eur. J. Pharmacol.
Further investigation of the in vivo pharmacological properties of the putative 5-HT1A antagonist, BMY 7378
Eur. J. Pharmacol.
Effects of (S)WAY 100135 on 5-HT levels in the ventral hippocampus of anaesthetized rat as measured by in vivo microdialysis
WAY 100635 reverses the decrease in 5-HT levels produced by the putative 5-HT1A antagonist, WAY 100135
Soc. Neurosci. Abstr.
Cited by (88)
The Role of 5-HT1A Receptor, and Nausea and Vomiting Relief by Cannabidiol (CBD), Cannabidiolic Acid (CBDA), and Cannabigerol (CBG)
2017, Handbook of Cannabis and Related Pathologies: Biology, Pharmacology, Diagnosis, and TreatmentExtending therapeutic use of psychostimulants: Focus on serotonin-1A receptor
2013, Progress in Neuro-Psychopharmacology and Biological Psychiatry5-HT1A receptor antagonists reduce food intake and body weight by reducing total meals with no conditioned taste aversion
2013, Pharmacology Biochemistry and BehaviorEvaluation of the behavioral and pharmacokinetic profile of SYA013, a homopiperazine analog of haloperidol in rats
2012, Pharmacology Biochemistry and BehaviorCitation Excerpt :Secondly, the dose of SYA013 used by us (0.08 mmol/kg) is smaller than that used by Depoortere (0.1 mmol/kg) for F15063. Indeed, others have used smaller doses (0.16 mg/kg) of WAY100,635 to reverse 8-OH-DPAT effects (Assie and Koek, 1996). A new instrument, the Catalepsy Test Chamber (Med Associates, Inc., St. Albans, VT), was used to assist in performing the classic catalepsy bar test with rats.
Mapping of CBV changes in 5-HT1A terminal fields by functional MRI in the mouse brain
2011, European NeuropsychopharmacologyCitation Excerpt :However, other studies using electrophysiological recording in vitro, demonstrated that WAY-100635 blocks the effect of 5-HT agonists in a dose-dependent fashion at both, post-synaptic 5-HT1A receptors in ascending 5-HT projection areas such as cingulate cortex, hippocampus, and amygdala, and somatodendritic 5-HT1A receptors located on dorsal raphe nucleus 5-HT neurons, but cannot activate the 5-HT1A receptor on its own. Studies in anesthetized animals further demonstrated that WAY-100635 does not increase extracellular 5-HT levels (Assié and Koek, 1996) or serotonergic firing in dorsal raphe nucleus (Fletcher et al., 1996). From these findings, we speculate that the weak CBV decrease elicited by WAY-100635 is independent of the 5-HT1A receptor.